Leerink Swann Equities Analysts Increase Earnings Estimates for Intercept Pharmaceuticals, Inc. (ICPT)
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Stock analysts at Leerink Swann raised their FY2017 EPS estimates for Intercept Pharmaceuticals in a research note issued on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($13.05) per share for the year, up from their prior forecast of ($14.80). Leerink Swann has a “Market Perform” rating and a $66.00 price objective on the stock. Leerink Swann also issued estimates for Intercept Pharmaceuticals’ Q4 2017 earnings at ($3.09) EPS, FY2018 earnings at ($13.10) EPS and FY2019 earnings at ($10.98) EPS.
A number of other research firms have also recently commented on ICPT. Royal Bank Of Canada assumed coverage on Intercept Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $244.00 price objective for the company. Laidlaw dropped their price objective on Intercept Pharmaceuticals from $118.00 to $90.00 and set a “hold” rating for the company in a research report on Friday, September 22nd. Cantor Fitzgerald upgraded Intercept Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $69.00 price objective for the company in a research report on Wednesday, November 1st. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Finally, Wedbush reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $153.76.
ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/leerink-swann-equities-analysts-increase-earnings-estimates-for-intercept-pharmaceuticals-inc-icpt/1687107.html.
Intercept Pharmaceuticals (NASDAQ ICPT) opened at $65.01 on Monday. Intercept Pharmaceuticals has a 52-week low of $54.98 and a 52-week high of $135.59. The company has a current ratio of 6.61, a quick ratio of 6.61 and a debt-to-equity ratio of 2.05.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 152.78% and a negative net margin of 344.74%. The business had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. During the same quarter last year, the business posted ($3.59) earnings per share. The business’s revenue for the quarter was up 697.9% on a year-over-year basis.
In other news, insider Lisa Bright sold 253 shares of Intercept Pharmaceuticals stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $111.31, for a total value of $28,161.43. Following the transaction, the insider now directly owns 23,324 shares of the company’s stock, valued at approximately $2,596,194.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO David Shapiro sold 1,250 shares of Intercept Pharmaceuticals stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the transaction, the chief marketing officer now directly owns 45,812 shares in the company, valued at $5,379,703.16. The disclosure for this sale can be found here. Insiders sold a total of 4,069 shares of company stock worth $325,974 over the last ninety days. Corporate insiders own 4.50% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its stake in shares of Intercept Pharmaceuticals by 0.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 14 shares in the last quarter. Public Employees Retirement Association of Colorado lifted its stake in shares of Intercept Pharmaceuticals by 1.1% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 43 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Intercept Pharmaceuticals by 1.8% during the 2nd quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock valued at $416,000 after buying an additional 62 shares during the period. WFG Advisors LP raised its holdings in shares of Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares during the period. Finally, Utah Retirement Systems raised its holdings in shares of Intercept Pharmaceuticals by 6.5% during the 2nd quarter. Utah Retirement Systems now owns 3,300 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 200 shares during the period. 82.69% of the stock is currently owned by institutional investors and hedge funds.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.